|
Time-Dependent Inhibitory Effect of Non-Nucleosidic Telomerase Inhibitor on NB4 Cell Proliferation through Transcriptional Suppression of Catalytic Subunit
|
D. Bashash   , S.H. Ghaffari , M. Kazerani , K. Hazaveh , K. Alimoghaddam , A. Ghavamzadeh |
|
|
| Keywords: Key words: Acute Promyelocytic Leukemia, BIBR1532, Telomerase |
|
|
Full-Text [PDF 680 kb]
(1968 Downloads)
| Abstract (HTML) (10083 Views)
|
Type of Study: Research |
Subject:
Hematology
Published: 2013/12/18
|
|
|
|
|
|
|
Full-Text: (2102 Views) |
References:
- Mantadakis E, Samonis G, Kalmanti M. A comprehensive review of acute promyelocytic leukemia in children. Acta Haematol 2008; 119(2): 73-82.
- Martens JH, Brinkman AB, Simmer F, Francoijs KJ, Nebbioso A, Ferrara F, et al. PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell 2010; 17(2): 173-85.
- de Thé H, Chen Z. Acute promyelocytic leukaemia: novel insights into the mechanisms of cure. Nat Rev Cancer 2010; 10(11): 775-83.
- Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 2010; 328(5975): 240-3.
- Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100(1): 57-70.
- Kelland L. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Clin Cancer Res 2007; 13(17): 4960-3.
- Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nat Med 2006; 12(10): 1133-8.
- Mason M, Schuller A, Skordalakes E. Telomerase structure function. Curr Opin Struct Biol 2011; 21(1): 92-100.
- Wojtyla A, Gladych M, Rubis B. Human telomerase activity regulation. Mol Biol Rep 2011; 38(5): 3339-49.
- Damm K, Hemmann U, Garin-Chesa P, Hauel N,
Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 2001; 20(24): 6958-68.
- Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem 2002; 277(18): 15566-72.
- Shay JW, Keith WN. Targeting telomerase for cancer therapeutics. Br J Cancer 2008; 98(4): 677-83.
- Ghaffari SH, Shayan-Asl N, Jamialahmadi AH, Alimoghaddam K, Ghavamzadeh A. Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival. Ann Oncol 2008; 19(11): 1927-34.
- Horikawa I, Barrett JC. Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 2003; 24(7): 1167-76.
- Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266(5193): 2011-5.
- Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997; 33(5): 787-91.
- Zeng Z, Min B, Huang J, Hong K, Yang Y, Collins K, et al. Structural basis for Tetrahymena telomerase
processivity factor Teb1 binding to single-stranded telomeric-repeat DNA. Proc Natl Acad Sci U S A 2011; 108(51): 20357-61.
- Ouellette MM, Wright WE, Shay JW. Targeting telomerase-expressing cancer cells. J Cell Mol Med 2011; 15(7): 1433-42.
- Deville L, Hillion J, Ségal-Bendirdjian E. Telomerase regulation in hematological cancers: a matter of stemness? Biochim Biophys Acta 2009; 1792(4): 229-39.
- Lengfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. Leukemia 2012; 26(3): 433-42.
- Mueller S, Hartmann U, Mayer F, Balabanov S, Hartmann JT, Brummendorf TH, et al. Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumors. Invest New Drugs 2007; 25(6): 519-24.
- El-Daly H, Kull M, Zimmermann S, Pantic M, Waller CF, Martens UM. Selective cytotoxicity and telomere damage in leukemia cells using the telomerase inhibitor BIBR1532. Blood 2005; 105(4): 1742-9.
- Huh HJ, Huh JW, Yoo ES, Seong CM, Lee M, Hong KS, et al. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol 2005; 79(4): 267-73.
|
Sci J Iran Blood Transfus Organ 2014; 10(4): 335-346
|
Time-Dependent Inhibitory Effect of Non-Nucleosidic
Telomerase Inhibitor on NB4 Cell Proliferation through Transcriptional Suppression of Catalytic Subunit
Bashash D.1, Ghaffari S.H.2, Kazerani M.2, HezavehK.2, Alimoghaddam K.2,
Ghavamzadeh A.2
1Faculty of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2Hematology, Oncology and Stem Cell Research Center of Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran
Abstract
Background and Objectives
Since stimulated telomerase activity provides nearly all of human malignancies including acute promyelocytic leukemia (APL) with unlimited proliferative potential, targeting telomerase seems to be an effective approach in cancer treatment. In this regard, BIBR1532, a small-molecule inhibitor of telomerase, has been shown to increase the therapeutic window of current chemotherapeutic regimens. This study was aimed to investigate the effects of BIBR1532 on cell proliferation as well as transcriptional alteration of hTERT (the catalytic subunit of telomerase).
Materials and Methods
NB4 leukemic cells were treated with various concentrations of BIBR1532 and succeeding trypan blue exclusion assay, BrdU cell proliferation assay, and quantitative real-time PCR were applied to investigate cell viability index, cell proliferation and time-dependent alteration of hTERT mRNA levels.
Results
BIBR1532 decreased cell viability index and exerted an antiproliferative effect against NB4 leukemic cells; we found that exposing cells with BIBR1532 at 30, 60 and 90 μM for 72 h inhibited DNA synthesis rate by 24, 45 and 70%, respectively. Furthermore, transcriptional suppression of hTERT was found upon NB4 treatment by BIBR1532 in a time- and dose-dependent manner.
Conclusions
Based on the short telomere length and high terlomerase activity in APL as well as antiproliferative effect of BIBR1532 against NB4 cells, anti-telomerase-based therapy might be regarded as a successful strategy in APL therapy.
Key words: Acute Promyelocytic Leukemia, BIBR1532, Telomerase
Received: 25 Aug 2012
Accepted: 20 Nov 2012
Correspondence: Ghaffari SH., PhD of Molecular Genetics. Associate Professor of Hematology, Oncology and Stem Cell Research Center, Tehran University of Medical Sciences, Shariati Hospital, Kargar Street.
Postal code: 14111, Tehran, Iran. Tel: (+9821) 84902665; Fax: (+9821) 88004140
E-mail:
shghaffari@tums.ac.ir
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Bashash D, Ghaffari S, Kazerani M, Hazaveh K, Alimoghaddam K, Ghavamzadeh A. Time-Dependent Inhibitory Effect of Non-Nucleosidic Telomerase Inhibitor on NB4 Cell Proliferation through Transcriptional Suppression of Catalytic Subunit . Sci J Iran Blood Transfus Organ 2014; 10 (4) :335-346 URL: http://bloodjournal.ir/article-1-825-en.html
|
.jpg)
.png)
